FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2531608462> ?p ?o ?g. }

• W2531608462 endingPage "544" @default.
• W2531608462 startingPage "544" @default.
• W2531608462 abstract "Abstract Background: Drepagreffe is a French national prospective trial involving 67 sickle cell anemia (SCA)-children with a history of abnormal cerebral arterial velocities by TCD, and comparing for the first time the outcome of cerebral vasculopathy following transfusion program (TP) or transplantation (HSCT). Inclusion criteria at enrollment were children with SCA (SS/Sb0), younger than 15 years, with a history of abnormal cerebral arterial velocities (TAMMX ≥ 200 cm/sec) and placed on long-term TP, with at least one non-SCA sibling, and with parents accepting HLA-typing and HSCT if a genoidentical donor was available. The 2 arms (TP/HSCT) were defined by the random-availability of a genoidentical donor. Seven of the 67 patients had a history of stroke. Transplanted patients (n=32) received a conditioning regimen of Busilvex-CY 200 mg/kg and 20 mg/kg rabbit Thymoglobulin, with CSA and a short course of MTX or MMF for GvHD prophylaxis. In the TP arm (n=35), HbS% was maintained at < 30%, with an Hb at 9-11g/dL. At enrollment and 12 months post-enrollment, blood screening, Doppler, and cerebral MRI/MRA were performed along with cognitive performance testing, the latter being done in parallel in the non-SCA siblings. Preliminary findings on cerebral velocities as the primary endpoint were reported at the last ASH meeting (abstract 67237), and demonstrated that all patients were alive at one year and that the 32 transplanted patients had no chronic GVHD and the same hemoglobin profile as their donor. Velocities were significantly lower post-HSCT than under TP (p <0.001), and were normalized in a greater number of patients (p =0.003). Patients and Methods: We report here the cerebral imaging (MRI/MRA) and cognitive performance data performed at enrollment and after 12 months. The scoring applied for MRI was: 3 = territorial, 2 = borderzone (cortical and subcortical), 1 = white matter or basal ganglia infarcts, 0 to 3 = atrophia, and for MRA: 1 = mild stenosis (25-49%), 2 = moderate stenosis (50-74%), 3 = severe stenosis (75-99%), 4 = occlusion for each artery and 0 to 2 for Moya presence. Cognitive testing using the WPPSI-3 (3-6 yr), WISC-4 (7-16 yr) or WAIS-3 (>16 yr) scales, depending on the age, was performed in patients and in siblings when possible. Results: MRI/MRA data were available in 66/67 patients. At enrollment (M0), ischemic lesions and stenoses were present in 25 and 35/66 patients, respectively. Cognitive testing was obtained in 64 patients and 56 siblings. Paired analysis with siblings (Table 1) showed significant differences in Verbal Comprehension Index (VCI) with a mean difference of 7.6±14.5(p =0.0004), Processing Speed Index (PSI) 6.3±20.5 (p =0.04), and Full Scale IQ (FSIQ) 7.3±15.0 (p =0.01). After exclusion of the 7 patients with stroke history, significant differences were still observed in VCI (p =0.013) and FSIQ (p =0.019). Patient cognitive performance indexes were correlated negatively and significantly with the MRI and MRA scores (Table 2). At post-enrollment (M12),ischemic lesions and stenoses were present in 26/66 patients. The mean variation in MRI and MRA scores between M12 and M0 was not significantly different between the 2 arms (Table 3). The cognitive tests were performed at M12 in 60 patients (Table 4) and the performance indexes were improved in the TP compared to the HSCT arm, but only significantly for FSIQ. Conclusion This first prospective trial initially showed that HSCT reduces more significantly the cerebral velocities at M12 and in a higher proportion of patients than TP. Here, we show that patients with a history of abnormal cerebral velocities had significantly lower cognitive performances than their siblings, even in the absence of stroke history; however, there was no significant difference between the 2 arms for the outcomes of ischemic lesions and stenosis at M0 and M12. The fact that cognitive performances were improved in the TP compared to the HSCT arm might be explained by the stress of the HSCT procedure and the lack of schooling during this period. Despite the higher ability of HSCT to decrease velocities at M12 compared to TP, a longer follow-up will be required to demonstrate its effect on stenosis and cognitive performances; therefore, patients will be reassessed at 3 years post-HSCT. Disclosures Bernaudin: Novartis: Research Funding." @default.
• W2531608462 created "2016-10-21" @default.
• W2531608462 creator A5004015988 @default.
• W2531608462 creator A5006102363 @default.
• W2531608462 creator A5008011056 @default.
• W2531608462 creator A5012691135 @default.
• W2531608462 creator A5014678847 @default.
• W2531608462 creator A5017582939 @default.
• W2531608462 creator A5022244317 @default.
• W2531608462 creator A5025294468 @default.
• W2531608462 creator A5026244294 @default.
• W2531608462 creator A5033760104 @default.
• W2531608462 creator A5039924900 @default.
• W2531608462 creator A5042260467 @default.
• W2531608462 creator A5042640180 @default.
• W2531608462 creator A5048120403 @default.
• W2531608462 creator A5052072616 @default.
• W2531608462 creator A5052673276 @default.
• W2531608462 creator A5053014054 @default.
• W2531608462 creator A5054424256 @default.
• W2531608462 creator A5058423103 @default.
• W2531608462 creator A5058527857 @default.
• W2531608462 creator A5059187541 @default.
• W2531608462 creator A5070058945 @default.
• W2531608462 creator A5074830346 @default.
• W2531608462 creator A5075603895 @default.
• W2531608462 creator A5089617150 @default.
• W2531608462 creator A5089693336 @default.
• W2531608462 creator A5090039601 @default.
• W2531608462 creator A5091811855 @default.
• W2531608462 date "2015-12-03" @default.
• W2531608462 modified "2023-10-03" @default.
• W2531608462 title "French National Drepagreffe Trial: Cognitive Performances and Neuroimaging at Enrollment and after 12 Months on Transfusion Program or Transplantation (AP-HP: NCT 01340404)" @default.
• W2531608462 doi "https://doi.org/10.1182/blood.v126.23.544.544" @default.
• W2531608462 hasPublicationYear "2015" @default.
• W2531608462 type Work @default.
• W2531608462 sameAs 2531608462 @default.
• W2531608462 citedByCount "5" @default.
• W2531608462 countsByYear W25316084622017 @default.
• W2531608462 countsByYear W25316084622018 @default.
• W2531608462 countsByYear W25316084622020 @default.
• W2531608462 crossrefType "journal-article" @default.
• W2531608462 hasAuthorship W2531608462A5004015988 @default.
• W2531608462 hasAuthorship W2531608462A5006102363 @default.
• W2531608462 hasAuthorship W2531608462A5008011056 @default.
• W2531608462 hasAuthorship W2531608462A5012691135 @default.
• W2531608462 hasAuthorship W2531608462A5014678847 @default.
• W2531608462 hasAuthorship W2531608462A5017582939 @default.
• W2531608462 hasAuthorship W2531608462A5022244317 @default.
• W2531608462 hasAuthorship W2531608462A5025294468 @default.
• W2531608462 hasAuthorship W2531608462A5026244294 @default.
• W2531608462 hasAuthorship W2531608462A5033760104 @default.
• W2531608462 hasAuthorship W2531608462A5039924900 @default.
• W2531608462 hasAuthorship W2531608462A5042260467 @default.
• W2531608462 hasAuthorship W2531608462A5042640180 @default.
• W2531608462 hasAuthorship W2531608462A5048120403 @default.
• W2531608462 hasAuthorship W2531608462A5052072616 @default.
• W2531608462 hasAuthorship W2531608462A5052673276 @default.
• W2531608462 hasAuthorship W2531608462A5053014054 @default.
• W2531608462 hasAuthorship W2531608462A5054424256 @default.
• W2531608462 hasAuthorship W2531608462A5058423103 @default.
• W2531608462 hasAuthorship W2531608462A5058527857 @default.
• W2531608462 hasAuthorship W2531608462A5059187541 @default.
• W2531608462 hasAuthorship W2531608462A5070058945 @default.
• W2531608462 hasAuthorship W2531608462A5074830346 @default.
• W2531608462 hasAuthorship W2531608462A5075603895 @default.
• W2531608462 hasAuthorship W2531608462A5089617150 @default.
• W2531608462 hasAuthorship W2531608462A5089693336 @default.
• W2531608462 hasAuthorship W2531608462A5090039601 @default.
• W2531608462 hasAuthorship W2531608462A5091811855 @default.
• W2531608462 hasConcept C126322002 @default.
• W2531608462 hasConcept C127413603 @default.
• W2531608462 hasConcept C141071460 @default.
• W2531608462 hasConcept C187212893 @default.
• W2531608462 hasConcept C2777408962 @default.
• W2531608462 hasConcept C2777630719 @default.
• W2531608462 hasConcept C2780645631 @default.
• W2531608462 hasConcept C2781413609 @default.
• W2531608462 hasConcept C2909675724 @default.
• W2531608462 hasConcept C2911091166 @default.
• W2531608462 hasConcept C71924100 @default.
• W2531608462 hasConcept C78519656 @default.
• W2531608462 hasConceptScore W2531608462C126322002 @default.
• W2531608462 hasConceptScore W2531608462C127413603 @default.
• W2531608462 hasConceptScore W2531608462C141071460 @default.
• W2531608462 hasConceptScore W2531608462C187212893 @default.
• W2531608462 hasConceptScore W2531608462C2777408962 @default.
• W2531608462 hasConceptScore W2531608462C2777630719 @default.
• W2531608462 hasConceptScore W2531608462C2780645631 @default.
• W2531608462 hasConceptScore W2531608462C2781413609 @default.
• W2531608462 hasConceptScore W2531608462C2909675724 @default.
• W2531608462 hasConceptScore W2531608462C2911091166 @default.
• W2531608462 hasConceptScore W2531608462C71924100 @default.
• W2531608462 hasConceptScore W2531608462C78519656 @default.
• W2531608462 hasIssue "23" @default.
• W2531608462 hasLocation W25316084621 @default.
• W2531608462 hasOpenAccess W2531608462 @default.
• W2531608462 hasPrimaryLocation W25316084621 @default.

• next